[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endometrial-cancer-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endometrial-cancer-stage-iv":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100607526","plant-based-nutrition-for-breast-or-endometrial-cancer-100607526",false,"NCT07189702","Plant-Based Nutrition for Breast or Endometrial Cancer","A Randomized Controlled Trial of Behavioral Education and Nutrition Delivery in Women With Metastatic Breast and Endometrial Cancer. (The BEND-MBEC Study)","BEND-MBEC","Inclusion Criteria: • Female sex (as assigned at birth), aged 18 years or older\n\n* A confirmed diagnosis of endometrial or metastatic breast cancer. All subtypes are eligible\n* Treating oncologist approval and expected survival of at least six months\n* Undergoing any systemic treatment including hormonal, cytotoxic, targeted monoclonal antibody or small molecule kinase inhibitors or any combination of the above. Women who have active cancer and have been recommended but declined systemic treatment are also eligible.\n* Willing to adopt a strict, whole-foods, plant-based diet\n* Willing and able to comply with the WFPB protocol for the duration of the study including scheduled testing, Zoom meetings, and office visits\n* Able to speak and read English fluently.\n* Women with plans for radiation therapy or surgery are also eligible provided that they meet all other eligibility criteria.\n\nExclusion Criteria: • BMI ≤ 20.0 kg\u002Fm2\n\n* Inability to tolerate a normal diet\n* Active malabsorption syndrome at time of consent, as determined by study physicians (i.e. Crohn's disease, bowel surgery)\n* Any food allergies or intolerances that would interfere with study compliance\n* Recent consumption (in the past six months) of a vegan diet\n* eGFR \\\u003C 30 on ≥ two lab tests in the past six months\n* Serum potassium \\> 5.4 in the past six months\n* Current insulin or sulfonylurea use\n* Current warfarin use (non-vitamin K antagonist allowed)\n* High-risk alcohol use (\\>7 drinks\u002Fwk)\n* Illicit substance use (not including marijuana)\n* Cognitive impairment or psychiatric disorder impairing ability to give consent.","FEMALE","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a randomized controlled trial of a whole food, plant-based (WFPB) dietary intervention among women with metastatic breast or endometrial cancer.",[27,28],"Breast Cancer Metastatic","Endometrial Cancer Stage IV",[30,31,32,33,34,35,36],"Metastatic","Metastatic Breast","Metastatic Endometrial","Breast Stage IV","Endometrial Stage IV","Nutrition","Plant-Based Nutrition","NOT_YET_RECRUITING","2026-04-07",{"date":40,"type":41},"2026-04-08","ACTUAL",{"date":43,"type":21},"2026-12",{"date":45,"type":21},"2030-12",{"name":47,"class":48},"University of Rochester","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100333482","promote-study-prediction-of-response-of-hormonal-treatment-in-advanced-and-recurrent-endometrial-cancer-100333482","NCT03621904","PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer","PROMOTE","Inclusion Criteria:\n\n* Advanced stage (FIGO stage III and IV) and recurrent endometrial cancer\n* All histologic types of endometrial carcinoma\n* Planned treatment with any type of hormonal therapy\n* Biopsy taken within 120 days prior to start of hormonal therapy with no intercurrent therapy between biopsy and start of hormonal therapy.\n\nExclusion Criteria:\n\n* Adjuvant hormonal therapy started following complete resection of endometrial carcinoma\n* Synchronous use of hormonal therapy for other indications\n* Endometrial sarcoma or endometrial stroma cell sarcoma","110 Years",{"count":58,"type":21},150,"2 Years","OBSERVATIONAL","The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy",[63,28,64],"Endometrial Cancer Stage III","Endometrial Cancer Recurrent",[66,67,68,69],"Hormonal therapy","Endocrine therapy","Translational research","Tumor factors","RECRUITING","2023-01-17",{"date":73,"type":41},"2023-01-18",{"date":75,"type":41},"2022-10-15",{"date":77,"type":21},"2027-09-01",{"name":79,"class":48},"Radboud University Medical Center",1]